Rx License-Rx

14-7086-tpNCS

Thioamide-modified peptides for stabilized therapeutics and drug development

Natural bioactive peptides and hormones with thioamide substitutions at cleavage sites for improved pharmacokinetics Problem: Natural bioactive peptides are attractive lead pharmaceutical compounds, but peptides are subjected to rapid proteolysis in vivo. The majority of the time spent in peptide biologic drug development seeks to reduce this protein degradation, while maintaining activity. Solution: Researchers in the Petersson lab have developed a straightforward strategy to modify bioactive peptides in a minimally invasive manner. A single atom thioamide (O-to-S) substitution at the cleavage site of the peptide can decrease proteolysis rates up to 1000x to improve stability while maintaining peptide activity and function. The researchers applied this strategy to the incretin hormone glucagon-like peptide 1 (GLP-1), which stimulates insulin and suppresses glucagon secretion. GLP-1 is inactivated in vivo by dipeptidyl peptidase...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Cardiometabolic

Indication: Diabetes

Modality: Small Molecule

Focus tags: Cardiometabolic

Technology tags: Small Molecule, Biologic, Drug Delivery, Biomanufacturing

Mechanism:

Development stage: Preclinical

Patent status: US 11,891,425 US 10,189,884 US 10,947,290

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Cardiometabolic. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Diabetes. Public description: Natural bioactive peptides and hormones with thioamide substitutions at cleavage sites for improved pharmacokinetics Problem: Natural bioactive peptides are attractive lead pharmaceutical compounds, but peptides are subjected to rapid.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Turn delivery into the asset by choosing a toxicity-sensitive local indication

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Novartis — Broad modality appetite and academic-origin BD history. Takeda — Translational science focus and partnership-friendly structure. Sanofi — Immunology, rare disease, and platform-technology BD appetite.

Development Strategy to Increase PoS

First indication: Diabetes

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Turn delivery into the asset by choosing a toxicity-sensitive local indication Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Turn delivery into the asset by choosing a toxicity-sensitive local indication

Best next experiment: Run the smallest independent study that validates: Run biodistribution and local tolerability first, then attach the platform to a known active payload instead of inventing a new drug story.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.